Table 1. Patients characteristics, histopathological and laboratory examination and treatment.
Case no. | Age (yr) | Sex | DD (mo) | Angioedema | Biopsy | DIF | C3 | ANA | Previous drugs (mg/d) | NOI | TCR (wk) |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 41 | F | 12 | No | LV | N/A | N | (−) | Rupatadin 10 | 8 | 4 |
Colchicine 1.5 | |||||||||||
Hydroxychloroquine 400 | |||||||||||
Dapsone 100 | |||||||||||
2 | 34 | F | 24 | Yes | LV | Positive C1q+ | N | (−) | Cetirizin 10 | 12 | 4 |
Prednisone 16 | |||||||||||
Colchicine 1.5 | |||||||||||
3 | 26 | M | 36 | Yes | LV | N/A | N | (−) | Levocetirizin 5 | 14 | 4 |
Cyclosporine 200 | |||||||||||
4 | 58 | F | 12 | Yes | LV | Positive C3+C1q+ | N | (−) | Ebastine 10 | 5 | 4 |
DD: duration of disease, DIF: direct immunofluorescence examination, ANA: antinuclear antibody, NOI: number of omalizumab injections, TCR: time to complete response, F: female, M: male, LV: leukocytoclastic vasculitis, N/A: nonavailable, N: normal.